Literature DB >> 15964811

Histone acetyltransferase activity of p300 is required for transcriptional repression by the promyelocytic leukemia zinc finger protein.

Fabien Guidez1, Louise Howell, Mark Isalan, Marek Cebrat, Rhoda M Alani, Sarah Ivins, Itsaso Hormaeche, Melanie J McConnell, Sarah Pierce, Philip A Cole, Jonathan Licht, Arthur Zelent.   

Abstract

Histone acetyltransferase (HAT) activities of proteins such as p300, CBP, and P/CAF play important roles in activation of gene expression. We now show that the HAT activity of p300 can also be required for down-regulation of transcription by a DNA binding repressor protein. Promyelocytic leukemia zinc finger (PLZF), originally identified as a fusion with retinoic acid receptor alpha in rare cases of all-trans-retinoic acid-resistant acute promyelocytic leukemia, is a transcriptional repressor that recruits histone deacetylase-containing corepressor complexes to specific DNA binding sites. PLZF associates with p300 in vivo, and its ability to repress transcription is specifically dependent on HAT activity of p300 and acetylation of lysines in its C-terminal C2-H2 zinc finger motif. An acetylation site mutant of PLZF does not repress transcription and is functionally deficient in a colony suppression assay despite retaining its abilities to interact with corepressor/histone deacetylase complexes. This is due to the fact that acetylation of PLZF activates its ability to bind specific DNA sequences both in vitro and in vivo. Taken together, our results indicate that a histone deacetylase-dependent transcriptional repressor can be positively regulated through acetylation and point to an unexpected role of a coactivator protein in transcriptional repression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15964811      PMCID: PMC1156991          DOI: 10.1128/MCB.25.13.5552-5566.2005

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  81 in total

Review 1.  Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia.

Authors:  A Melnick; J D Licht
Journal:  Blood       Date:  1999-05-15       Impact factor: 22.113

2.  Amino-terminal protein-protein interaction motif (POZ-domain) is responsible for activities of the promyelocytic leukemia zinc finger-retinoic acid receptor-alpha fusion protein.

Authors:  S Dong; J Zhu; A Reid; P Strutt; F Guidez; H J Zhong; Z Y Wang; J Licht; S Waxman; C Chomienne; Z Chen; A Zelent; S J Chen
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-16       Impact factor: 11.205

3.  DNA recognition code of transcription factors in the helix-turn-helix, probe helix, hormone receptor, and zinc finger families.

Authors:  M Suzuki; N Yagi
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

4.  Toward a code for the interactions of zinc fingers with DNA: selection of randomized fingers displayed on phage.

Authors:  Y Choo; A Klug
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-08       Impact factor: 11.205

5.  The promyelocytic leukemia zinc finger (PLZF) protein binds DNA in a high molecular weight complex associated with cdc2 kinase.

Authors:  H J Ball; A Melnick; R Shaknovich; R A Kohanski; J D Licht
Journal:  Nucleic Acids Res       Date:  1999-10-15       Impact factor: 16.971

6.  Modulation of CREB binding protein function by the promyelocytic (PML) oncoprotein suggests a role for nuclear bodies in hormone signaling.

Authors:  V Doucas; M Tini; D A Egan; R M Evans
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

7.  Negative control of p53 by Sir2alpha promotes cell survival under stress.

Authors:  J Luo; A Y Nikolaev; S Imai; D Chen; F Su; A Shiloh; L Guarente; W Gu
Journal:  Cell       Date:  2001-10-19       Impact factor: 41.582

8.  Leukemia translocation gene, PLZF, is expressed with a speckled nuclear pattern in early hematopoietic progenitors.

Authors:  A Reid; A Gould; N Brand; M Cook; P Strutt; J Li; J Licht; S Waxman; R Krumlauf; A Zelent
Journal:  Blood       Date:  1995-12-15       Impact factor: 22.113

9.  A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A.

Authors:  X J Yang; V V Ogryzko; J Nishikawa; B H Howard; Y Nakatani
Journal:  Nature       Date:  1996-07-25       Impact factor: 49.962

10.  Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase.

Authors:  S Kato; H Endoh; Y Masuhiro; T Kitamoto; S Uchiyama; H Sasaki; S Masushige; Y Gotoh; E Nishida; H Kawashima; D Metzger; P Chambon
Journal:  Science       Date:  1995-12-01       Impact factor: 47.728

View more
  43 in total

1.  Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor.

Authors:  Erin M Bowers; Gai Yan; Chandrani Mukherjee; Andrew Orry; Ling Wang; Marc A Holbert; Nicholas T Crump; Catherine A Hazzalin; Glen Liszczak; Hua Yuan; Cecilia Larocca; S Adrian Saldanha; Ruben Abagyan; Yan Sun; David J Meyers; Ronen Marmorstein; Louis C Mahadevan; Rhoda M Alani; Philip A Cole
Journal:  Chem Biol       Date:  2010-05-28

2.  PLZF regulates CCR6 and is critical for the acquisition and maintenance of the Th17 phenotype in human cells.

Authors:  Satya P Singh; Hongwei H Zhang; Hsinyi Tsang; Paul J Gardina; Timothy G Myers; Vijayaraj Nagarajan; Chang Hoon Lee; Joshua M Farber
Journal:  J Immunol       Date:  2015-04-01       Impact factor: 5.422

3.  BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy.

Authors:  Leandro C Cerchietti; Katerina Hatzi; Eloisi Caldas-Lopes; Shao Ning Yang; Maria E Figueroa; Ryan D Morin; Martin Hirst; Lourdes Mendez; Rita Shaknovich; Philip A Cole; Kapil Bhalla; Randy D Gascoyne; Marco Marra; Gabriela Chiosis; Ari Melnick
Journal:  J Clin Invest       Date:  2010-11-01       Impact factor: 14.808

4.  Phosphatidylinositol 3-kinase/Akt pathway targets acetylation of Smad3 through Smad3/CREB-binding protein interaction: contribution to transforming growth factor beta1-induced Epstein-Barr virus reactivation.

Authors:  Lassad Oussaief; Aurélie Hippocrate; Vanessa Ramirez; Aurore Rampanou; Wei Zhang; David Meyers; Philip Cole; Ridha Khelifa; Irène Joab
Journal:  J Biol Chem       Date:  2009-07-09       Impact factor: 5.157

Review 5.  Chemical probes for histone-modifying enzymes.

Authors:  Philip A Cole
Journal:  Nat Chem Biol       Date:  2008-10       Impact factor: 15.040

Review 6.  Protein lysine acetylation by p300/CBP.

Authors:  Beverley M Dancy; Philip A Cole
Journal:  Chem Rev       Date:  2015-01-16       Impact factor: 60.622

7.  Corepressive action of CBP on androgen receptor transactivation in pericentric heterochromatin in a Drosophila experimental model system.

Authors:  Yue Zhao; Ken-ichi Takeyama; Shun Sawatsubashi; Saya Ito; Eriko Suzuki; Kaoru Yamagata; Masahiko Tanabe; Shuhei Kimura; Sally Fujiyama; Takashi Ueda; Takuya Murata; Hiroyuki Matsukawa; Yuko Shirode; Alexander P Kouzmenko; Feng Li; Testuya Tabata; Shigeaki Kato
Journal:  Mol Cell Biol       Date:  2008-12-15       Impact factor: 4.272

8.  PLZF/ZBTB16, a glucocorticoid response gene in acute lymphoblastic leukemia, interferes with glucocorticoid-induced apoptosis.

Authors:  Muhammad Wasim; Michela Carlet; Muhammad Mansha; Richard Greil; Christian Ploner; Alexander Trockenbacher; Johannes Rainer; Reinhard Kofler
Journal:  J Steroid Biochem Mol Biol       Date:  2010-05-06       Impact factor: 4.292

9.  STAMP alters the growth of transformed and ovarian cancer cells.

Authors:  Yuanzheng He; John A Blackford; Elise C Kohn; S Stoney Simons
Journal:  BMC Cancer       Date:  2010-04-07       Impact factor: 4.430

10.  Promyelocytic leukemia zinc finger protein regulates interferon-mediated innate immunity.

Authors:  Dakang Xu; Michelle Holko; Anthony J Sadler; Bernadette Scott; Shigeki Higashiyama; Windy Berkofsky-Fessler; Melanie J McConnell; Pier Paolo Pandolfi; Jonathan D Licht; Bryan R G Williams
Journal:  Immunity       Date:  2009-06-11       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.